Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 395 clinical trials
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer (DB-06)

This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor (HER)2-low, hormone receptor (HR) positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting.

  • 06 May, 2022
  • 224 locations
Breast Cancer Toxicity (CANTO)

The aims of the cohort will be to quantify impact of cancer treatments toxicities , and to generate predictors of chronic toxicity in patients with non-metastatic breast cancer. The

Accepts healthy volunteers
  • 19 Apr, 2022
  • 1 location
Capivasertib + Palbociclib + Fulvestrant for HR+/HER2- Advanced Breast Cancer (CAPItello-292). (CAPItello-292)

Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292).

  • 12 May, 2022
  • 15 locations
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer (CAPItello-291)

Phase III, double-blind, randomised study assessing the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer following recurrence or progression on or after AI therapy.

  • 06 May, 2022
  • 16 locations
Functional Precision Oncology for Metastatic Breast Cancer (FORESEE)

This is a pilot study to assess the feasibility of comprehensive genomic characterization and drug screening in metastatic breast cancer. The trial will seek to provide personalized genomic and

  • 26 Mar, 2022
  • 1 location
Exercise Treatment With Standard Therapy for Metastatic Breast Cancer

This study will test any good and bad effects of aerobic exercise performed while you are receiving the usual first-line treatment for metastatic breast cancer. The researchers think that

  • 18 Apr, 2022
  • 8 locations
Chemotherapy Monitoring by ctDNA in HER2- Metastatic Breast Cancer

This is a one-arm, single site, open-label phase II study. Patients will be enrolled in the screening step at the start of the second line of chemotherapy, and will undergo blood draws for ctDNA detection. Patients for whom ctDNA was successfully detected and found informative by the study executive board …

  • 30 Oct, 2021
  • 1 location
Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer (PEER)

This is an open-label, single-arm, multicenter, pilot study of pembrolizumab, exemestane, and leuprolide for subjects being resistant for front-line hormonal therapy for inoperable locally advanced or metastatic hormonal receptor positive (HR+)/ Human epidermal growth factor receptor 2 (HER2) negative breast cancer. All the patients will be included in the final …

  • 06 Feb, 2022
  • 1 location
  • 11 Mar, 2022
  • 1 location
Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer

This is a monocentric cohort study, prospective and interventional with minimal risks and constraints for advanced breast cancer. The planned interventions are collection of biological samples at different times. The study will aim to do a descriptive analysis of omics profiles evolution (tumor, volatile organic components) over time, before and …

  • 27 Jan, 2021
  • 1 location